Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

被引：155

作者：

Nuermberger, Eric ^{[1
]}

Tyagi, Sandeep ^{[1
]}

Tasneen, Rokeya ^{[1
]}

Williams, Kathy N. ^{[1
]}

Almeida, Deepak ^{[1
]}

Rosenthal, Ian ^{[1
]}

Grosset, Jacques H. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Ctr TB Res, Baltimore, MD USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2008年 / 52卷 / 04期

关键词：

D O I：

10.1128/AAC.00074-08

中图分类号：

Q93 [微生物学];

学科分类号：

071005 [微生物学]; 100705 [微生物与生化药学];

摘要：

PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more rapidly than the first-line regimen of rifampin, isoniazid, and pyrazinamide. If applicable to humans, regimens containing this combination may radically shorten the treatment of multidrug-resistant tuberculosis.

引用

收藏

页码：1522 / 1524

页数：3

相关论文

共 7 条

[1]

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice [J].

Matsumoto, Makoto ;

Hashizume, Hiroyuki ;

Tomishige, Tatsuo ;

Kawasaki, Masanori ;

Tsubouchi, Hidetsugu ;

Sasaki, Hirofumi ;

Shimokawa, Yoshihiko ;

Komatsu, Makoto .

PLOS MEDICINE, 2006, 3 (11) :2131-2144

[2]

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis [J].

Nuermberger, EL ;

Yoshimatsu, T ;

Tyagi, S ;

Williams, K ;

Rosenthal, I ;

O'Brien, RJ ;

Vernon, AA ;

Chaisson, RE ;

Bishai, WR ;

Grosset, JH .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (10) :1131-1134

[3]

Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis [J].

Nuermberger, EL ;

Yoshimatsu, T ;

Tyagi, S ;

O'Brien, RJ ;

Vernon, AN ;

Chaisson, RE ;

Bishai, WR ;

Grosset, JH .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (03) :421-426

[4]

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis [J].

Nuermberger, Eric ;

Rosenthal, Ian ;

Tyagi, Sandeep ;

Williams, Kathy N. ;

Almeida, Deepak ;

Peloquin, Charles A. ;

Bishai, William R. ;

Grosset, Jacques H. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (08) :2621-2625

[5]

The need for new drugs against tuberculosis - Obstacles, opportunities, and next steps [J].

O'Brien, RJ ;

Nunn, PP .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (05) :1055-1058

[6]

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis [J].

Stover, CK ;

Warrener, P ;

VanDevanter, DR ;

Sherman, DR ;

Arain, TM ;

Langhorne, MH ;

Anderson, SW ;

Towell, JA ;

Yuan, Y ;

McMurray, DN ;

Kreiswirth, BN ;

Barry, CE ;

Baker, WR .

NATURE, 2000, 405 (6789) :962-966

[7]

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis [J].

Tyagi, S ;

Nuermberger, E ;

Yoshimatsu, T ;

Williams, K ;

Rosenthal, I ;

Lounis, N ;

Bishai, W ;

Grosset, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2289-2293